<DOC>
	<DOCNO>NCT01035255</DOCNO>
	<brief_summary>The study evaluate efficacy safety LCZ696 compare enalapril morbidity mortality patient chronic heart failure ( NYHA Class II - IV EF = &lt; 35 % ) .</brief_summary>
	<brief_title>This Study Will Evaluate Efficacy Safety LCZ696 Compared Enalapril Morbidity Mortality Patients With Chronic Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Enalapril</mesh_term>
	<mesh_term>Enalaprilat</mesh_term>
	<mesh_term>LCZ 696</mesh_term>
	<criteria>Patients must give write informed consent assessment perform . Outpatients ≥ 18 year age , male female . Patients diagnosis CHF NYHA class IIIV reduce ejection fraction ( EF = &lt; 35 % ) elevate BNP . Patients must ACEI ARB stable dose least enalapril 10 mg/d equivalent least 4 week . Patients must treat βblocker , unless contraindicate tolerated , stable dose least 4 week . Use investigational drug time enrollment , within 30 day 5 halflives enrollment , whichever longer . History hypersensitivity allergy study drug , drug similar chemical class , ACEIs , ARBs , NEP inhibitor well know suspect contraindication study drug . Previous history intolerance recommend target dos ACEIs ARBs Known history angioedema . Requirement treatment ACEIs ARBs . Current acute decompensated HF ( exacerbation chronic HF manifest sign symptom may require intravenous therapy ) . Symptomatic hypotension and/or SBP &lt; 100 mmHg . Estimated GFR &lt; 30 mL/min/1.73m2 measure simplified MDRD formula Serum potassium &gt; 5.2 mmol/L . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>chronic heart failure</keyword>
	<keyword>cardiovascular death</keyword>
	<keyword>hospitalization</keyword>
	<keyword>outcome study</keyword>
	<keyword>BNP</keyword>
	<keyword>KCCQ</keyword>
	<keyword>eGFR</keyword>
</DOC>